Literature DB >> 26559833

Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA.

Alexander O Pasternak1, Laura K DeMaster2, Neeltje A Kootstra3, Peter Reiss4, Una O'Doherty2, Ben Berkhout5.   

Abstract

Cell-associated HIV unspliced RNA is an important marker of the viral reservoir. HIV gag RNA-specific assays are frequently used to monitor reservoir activation. Because HIV preferentially integrates into actively transcribed genes, some of the transcripts detected by these assays may not represent genuine HIV RNA but rather chimeric host-HIV readthrough transcripts. Here, we demonstrate that in HIV-infected patients on suppressive combination antiretroviral therapy, such host-derived transcripts do not significantly contribute to the HIV gag RNA level.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26559833      PMCID: PMC4702708          DOI: 10.1128/JVI.02597-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

3.  A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection.

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.

Authors:  Alexander O Pasternak; Karen W Adema; Margreet Bakker; Suzanne Jurriaans; Ben Berkhout; Marion Cornelissen; Vladimir V Lukashov
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

5.  Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.

Authors:  Philipp Kaiser; Beda Joos; Barbara Niederöst; Rainer Weber; Huldrych F Günthard; Marek Fischer
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

Review 6.  Towards an HIV-1 cure: measuring the latent reservoir.

Authors:  Katherine M Bruner; Nina N Hosmane; Robert F Siliciano
Journal:  Trends Microbiol       Date:  2015-03-05       Impact factor: 17.079

7.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

Authors:  Ole S Søgaard; Mette E Graversen; Steffen Leth; Rikke Olesen; Christel R Brinkmann; Sara K Nissen; Anne Sofie Kjaer; Mariane H Schleimann; Paul W Denton; William J Hey-Cunningham; Kersten K Koelsch; Giuseppe Pantaleo; Kim Krogsgaard; Maja Sommerfelt; Remi Fromentin; Nicolas Chomont; Thomas A Rasmussen; Lars Østergaard; Martin Tolstrup
Journal:  PLoS Pathog       Date:  2015-09-17       Impact factor: 6.823

8.  Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Authors:  Julian H Elliott; Fiona Wightman; Ajantha Solomon; Khader Ghneim; Jeffrey Ahlers; Mark J Cameron; Miranda Z Smith; Tim Spelman; James McMahon; Pushparaj Velayudham; Gregor Brown; Janine Roney; Jo Watson; Miles H Prince; Jennifer F Hoy; Nicolas Chomont; Rémi Fromentin; Francesco A Procopio; Joumana Zeidan; Sarah Palmer; Lina Odevall; Ricky W Johnstone; Ben P Martin; Elizabeth Sinclair; Steven G Deeks; Daria J Hazuda; Paul U Cameron; Rafick-Pierre Sékaly; Sharon R Lewin
Journal:  PLoS Pathog       Date:  2014-11-13       Impact factor: 6.823

9.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

View more
  18 in total

1.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Authors:  Michael A Moso; Jenny L Anderson; Samantha Adikari; Lachlan R Gray; Georges Khoury; Judy J Chang; Jonathan C Jacobson; Anne M Ellett; Wan-Jung Cheng; Suha Saleh; John J Zaunders; Damian F J Purcell; Paul U Cameron; Melissa J Churchill; Sharon R Lewin; Hao K Lu
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

3.  Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA.

Authors:  Feiyu Hong; Evgenia Aga; Anthony R Cillo; Aarika L Yates; Guillaume Besson; Elizabeth Fyne; Dianna L Koontz; Cheryl Jennings; Lu Zheng; John W Mellors
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

4.  TILDA: Tat/Rev Induced Limiting Dilution Assay.

Authors:  Cynthia Lungu; Francesco A Procopio
Journal:  Methods Mol Biol       Date:  2022

5.  Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection.

Authors:  Caroline Passaes; Héloïse M Delagreverie; Véronique Avettand-Fenoel; Annie David; Valérie Monceaux; Asma Essat; Michaela Müller-Trutwin; Darragh Duffy; Nathalie De Castro; Linda Wittkop; Christine Rouzioux; Jean-Michel Molina; Laurence Meyer; Constance Delaugerre; Asier Sáez-Cirión
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

6.  High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies.

Authors:  Bethany A Horsburgh; Eunok Lee; Bonnie Hiener; John-Sebastian Eden; Timothy E Schlub; Susanne von Stockenstrom; Lina Odevall; Jeffrey M Milush; Teri Liegler; Elizabeth Sinclair; Rebecca Hoh; Eli A Boritz; Daniel C Douek; Remi Fromentin; Nicolas Chomont; Steven G Deeks; Frederick M Hecht; Sarah Palmer
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

7.  Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques.

Authors:  Widade Ziani; Anya Bauer; Hong Lu; Xiaolei Wang; Xueling Wu; Katharine J Bar; Hui Li; Dongfang Liu; George M Shaw; Ronald S Veazey; Huanbin Xu
Journal:  J Virol       Date:  2021-04-12       Impact factor: 6.549

Review 8.  What do we measure when we measure cell-associated HIV RNA.

Authors:  Alexander O Pasternak; Ben Berkhout
Journal:  Retrovirology       Date:  2018-01-29       Impact factor: 4.602

Review 9.  Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.

Authors:  Amy E Baxter; Una O'Doherty; Daniel E Kaufmann
Journal:  Retrovirology       Date:  2018-02-02       Impact factor: 4.602

Review 10.  Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.

Authors:  Johann Plantin; Marta Massanella; Nicolas Chomont
Journal:  Retrovirology       Date:  2018-01-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.